Turmeric / curcumin
What studies of turmeric / curcumin found
At a glance, by condition
Long COVID: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty), for pain.
1 outcome rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Turmeric / curcumin might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Turmeric / curcumin · Long COVID is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Pain1 study · 1 (few people) person took turmeric / curcumin Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · three-year arc (few people)
Pain improved.
The evidence is very uncertain about the effect of Turmeric / curcumin on pain in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
Corona With Lyme: A Long COVID Case Study. (2023)
- People in the study
- 1 in the study
- Dose
- —
- Outcome
- severity and frequency of associated myalgias, headaches, and scalp allodynia
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Side effects
Side effects studies reported4 kinds
| Side effect | Studies that reported it |
|---|---|
| Anxiety or irritability | 1 study |
| Fatigue | 1 study |
| Headache | 1 study |
| Worse symptoms or a flare | 1 study |
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
42 to 100 mg at the start
- 2Top dose
Most often 42 mg (1 of 2 studies)
Doses across 2 studies
42 to 100 mg.
Each study’s dose, as printed
- 100 mg, chewable tablets once a day for 90 days Role of nutrient supplements in children with post-COVID condition: a retrospective preliminary observation and narrative review. (2025)
- 42 mg curcumin per capsule; total daily intake of 168 mg, two capsules twice daily for 8 weeks Potential Adjunctive Effects of Quercetin-Curcumin Co-Supplementation in Adults with Mild-to-Moderate Long COVID: Results from a Pragmatic Exploratory Real-World Clinical Study. (2026)
All papers
- Corona With Lyme: A Long COVID Case Study.2023 · case report · 1 in the study
Summary
This case report describes a previously healthy 26-year-old female medical student living in New York, NY, who developed long COVID after a presumed acute SARS-CoV-2 infection in March 2020, with a concurrent perceived early-disseminated Lyme disease infection. The three-year arc covers numerous trial-and-error treatments: a two-week regimen of doxycycline 100 mg twice a day, metformin escalation alongside diet modifications, graded compression stockings, breathing exercises, increases in caffeine and salt consumption with increased fluid intake, a horizontal cardio exercise program with rest periods, osteopathic manipulative treatment, cognitive behavioral therapy, sleep hygiene improvements, supplements (vitamin C, vitamin D, vitamin B12, B-complex, n-acetyl cysteine, turmeric extract), a two-dose Moderna mRNA COVID-19 vaccination course, and abortive headache therapies (Excedrin or Fioricet and prochlorperazine). The authors report a moderate reduction in cycle length and morning hypoglycemic symptoms with metformin, a moderate reduction in myalgias, headaches and scalp allodynia with osteopathic manipulative treatment, some relief of post-COVID headache, help with headache pain, orthostatic palpitations, fatigue and brain fog from abortive therapies plus caffeine, salt and fluid intake, moderate improvements in fatigue and brain fog in the first 24 hours after the first vaccine dose, moderate symptom alleviation from digital interventions, and small but recognizable differences in fatigue and cognition from sleep hygiene. No improvement in symptoms other than mild reduction in right shoulder pain followed the doxycycline regimen. Supplements provided no discernable benefit. The patient reports full recovery from long COVID with residual blurred vision and oligomenorrhea. Reported harms include worsening blurred vision, palpitations, heat intolerance and near-syncopal events; a moderate increase in fatigue and brain fog with a CGRP antagonist; fatigue exacerbation with traditional exercise rehabilitation; symptom re-exacerbations with compression stockings; and increased headache frequency and duration with n-acetyl cysteine. The abstract describes near-total remission.
- Potential Adjunctive Effects of Quercetin-Curcumin Co-Supplementation in Adults with Mild-to-Moderate Long COVID: Results from a Pragmatic Exploratory Real-World Clinical Study.2026 · combination: given with other treatments · 15 in the study · 14 with outcome data
Summary
This single-centre, open-label, single-arm, pragmatic exploratory study enrolled 15 adults with persistent Long COVID symptoms at outpatient clinics of Lady Reading Hospital—Medical Teaching Institution (LRH-MTI), Peshawar, Pakistan. Participants received oral quercetin–curcumin co-supplementation (Nasafytol®) plus standard care: each capsule contained 65 mg quercetin and Curcuma longa extract standardised to 42 mg curcumin, given as two capsules twice daily for 8 weeks (total daily intake 260 mg quercetin and 168 mg curcumin). There was no comparator group; assessments were at baseline and Week 8. Of 15 enrolled, 14 completed and one withdrew at their own discretion. The primary outcome was C19-YRS overall symptom burden. The C19-YRS total score decreased from median 50 to 32 (q = 0.018). FSS total score decreased from 41 to 28 (q = 0.006); BPI-SF pain severity decreased from 4.75 to 0 and pain interference from 4.14 to 0 (q = 0.006 for both); SF-36 PCS increased from 40.18 to 46.84 (q = 0.025). Cognitive function, anxiety, sleep quality, autonomic symptoms, and SF-36 MCS showed numerical changes that did not reach statistical significance. No serious adverse events were reported; three participants reported mild and transient gastrointestinal symptoms, and no participants discontinued due to adverse effects. Adherence was estimated to be greater than 90%. The authors state limitations including the non-randomised, open-label, single-arm design without blinding or a placebo/comparator group, precluding causal attribution.
- Role of nutrient supplements in children with post-COVID condition: a retrospective preliminary observation and narrative review.2025 · combination: given with other treatments · 1,243 in the study · 1,171 with outcome data
Summary
This retrospective preliminary observation and narrative review asked whether nutrient supplements affected long COVID in children. It was a retrospective sub-analysis of a previously published prospective follow-up cohort at a Post-COVID clinic in a third-level hospital in Rome, Italy, from February 2020 to October 2022. During the study period 1243 patients were enrolled; 1171 were in the six-month follow-up table. Children with persistent, disabling symptoms at three months after infection received oral lactoferrin and/or a Multi-Element Product (MEP) as chewable tablets once a day for 90 days. Treatment groups were MEP plus lactoferrin (152 started), lactoferrin alone (18), and MEP alone (9). The outcome was persistence of long COVID at six months following initial infection. As reported, MEP alone (OR 5.7, 95% CI 3.8–8.5) and MEP plus lactoferrin (OR 5.06, 95% CI 3.3–7.6) were associated with a lower risk of long COVID at six months than lactoferrin alone (OR 7.6, 95% CI 5.1–11.4). For therapy started six months or longer after infection, no statistically significant associations were found with Long Covid resolution. Harms were not reported. The authors state the study was retrospective and had no control group, so causality and spontaneous improvement cannot be distinguished.
- Attenuation of autoimmune responses to oxidative specific epitopes, but not nitroso-adducts, is associated with a better clinical outcome in Myalgic Encephalomyelitis/chronic fatigue syndrome.2014 · combination: given with other treatments · 76 in the study
Summary
Seventy-six ME/CFS patients admitted to the Maes Outpatient Clinics, Belgium, were selected for increased (> 2 SD) IgM responses to 3 OSEs or 3 NO-adducts. In this non-interventional study, all patients took a combination of NAIOS—L-carnitine, coenzyme Q10, taurine + lipoic acid, with or without curcumine + quercitine or N-acetyl-cysteine, zinc + glutamine—continued for 14.3 (±4.2) months. There was no separate comparison group; patients also received other care-as-usual treatments. The study measured FF scores and IgM responses to oleic acid, MDA, Pi, NOW, NO-arginine and NO-cysteinyl. Treatment was followed by significant reductions in IgM responses to oleic acid (F=9.03, p=0.004), MDA (F=13.12, p=0.001), Pi (F=20.28, p<0.001), NO-Cysteinyl (F=10.03, p=0.003), NO-Arginine (F=6.99, p=0.011) and NOW (F=6.19, p=0.016). In patients with endpoint FF<12, oleic acid and Pi responses fell more than in those with endpoint FF≥12. Antidepressant use had no significant effect (F=0.17, p=0.843). Harms were not reported. The authors state the non-interventional design could not standardize NAIOS and that supplement quality, content and bioavailability may have biased results.
- [Herbal treatment options for post-viral symptoms and long COVID].2026 · review
Summary
This narrative review asked which herbal medicines may be used for post-viral symptoms and Long-COVID. It was prepared by a working group of the Österreichische Gesellschaft für Phytotherapie; the search covered PubMed, PubPharm and Scopus from 2022 to 2024 and included 98 publications and 24 monographs. No patient total is reported: the paper is a review, not a trial, and it had no comparison group. It assigns medicinal plants to symptom complexes and summarises named studies. In those studies, a Rhodiola-Eleutherococcus-Schisandra combination was reported in randomised placebo-controlled trials to improve physical performance and renal function and to reduce pain and fatigue. A 2022 study reported reductions in fatigue, anosmia and persistent cough with 900 mg Schwarzkümmelöl, 2000 IE Vitamin D or both over 14 days; the Vitamin D combination strengthened the effect. Gillissen et al. 2013 reported a 12.3 % absolute risk reduction versus placebo with 300 mg ELOM-080 4‑mal täglich over 14 days; Fischer and Dethlefsen 2013 reported a ca. 22 % reduction in the Bronchitis Sum Score after 4 days versus placebo. Curcuma longa 1000 mg/Tag plus Boswellia serrata 300 mg/Tag reduced IBS symptoms in both groups, with dysbiosis improvement only in the group without COVID history. Side effects: Kasper et al. reported a better side-effect profile for Silexan and comparability with Paroxetin 20 mg/Tag; Zourek et al. described good tolerability and safety. For Schisandra, the text states CYP3A and P-gp inhibition and mentions 'unerwünschte Arzneimittelwechselwirkungen'. Worsening or stopping is not reported. The authors state that further clinical studies are needed.